GAMIDA CELL LTD (GMDA) Stock Fundamental Analysis

NASDAQ:GMDA • IL0011552663

0.0327 USD
-0.01 (-18.25%)
At close: Apr 5, 2024
0.032 USD
0 (-2.14%)
After Hours: 4/5/2024, 8:00:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Overall GMDA gets a fundamental rating of 2 out of 10. We evaluated GMDA against 521 industry peers in the Biotechnology industry. GMDA may be in some trouble as it scores bad on both profitability and health. GMDA is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • GMDA had negative earnings in the past year.
  • In the past year GMDA has reported a negative cash flow from operations.
  • In the past 5 years GMDA always reported negative net income.
  • In the past 5 years GMDA always reported negative operating cash flow.
GMDA Yearly Net Income VS EBIT VS OCF VS FCFGMDA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -61.65%, GMDA is doing worse than 60.48% of the companies in the same industry.
Industry RankSector Rank
ROA -61.65%
ROE N/A
ROIC N/A
ROA(3y)-61.87%
ROA(5y)-54.88%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GMDA Yearly ROA, ROE, ROICGMDA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 500 1K 1.5K 2K

1.3 Margins

  • GMDA has a Gross Margin of 18.53%. This is in the better half of the industry: GMDA outperforms 75.47% of its industry peers.
  • GMDA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 18.53%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GMDA Yearly Profit, Operating, Gross MarginsGMDA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K -4K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. Health

2.1 Basic Checks

  • GMDA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for GMDA has been increased compared to 1 year ago.
  • The debt/assets ratio for GMDA is higher compared to a year ago.
GMDA Yearly Shares OutstandingGMDA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M
GMDA Yearly Total Debt VS Total AssetsGMDA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

  • Based on the Altman-Z score of -8.53, we must say that GMDA is in the distress zone and has some risk of bankruptcy.
  • GMDA's Altman-Z score of -8.53 is on the low side compared to the rest of the industry. GMDA is outperformed by 74.45% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -8.53
ROIC/WACCN/A
WACC5.78%
GMDA Yearly LT Debt VS Equity VS FCFGMDA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M

2.3 Liquidity

  • A Current Ratio of 2.16 indicates that GMDA has no problem at all paying its short term obligations.
  • GMDA has a worse Current ratio (2.16) than 75.98% of its industry peers.
  • GMDA has a Quick Ratio of 2.09. This indicates that GMDA is financially healthy and has no problem in meeting its short term obligations.
  • GMDA has a Quick ratio of 2.09. This is in the lower half of the industry: GMDA underperforms 75.47% of its industry peers.
Industry RankSector Rank
Current Ratio 2.16
Quick Ratio 2.09
GMDA Yearly Current Assets VS Current LiabilitesGMDA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • GMDA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 49.19%, which is quite impressive.
EPS 1Y (TTM)49.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, GMDA will show a very strong growth in Earnings Per Share. The EPS will grow by 50.79% on average per year.
  • GMDA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 182.44% yearly.
EPS Next Y9.37%
EPS Next 2Y50.84%
EPS Next 3Y51.21%
EPS Next 5Y50.79%
Revenue Next Year808.75%
Revenue Next 2Y935.67%
Revenue Next 3Y499.3%
Revenue Next 5Y182.44%

3.3 Evolution

GMDA Yearly Revenue VS EstimatesGMDA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B
GMDA Yearly EPS VS EstimatesGMDA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 6

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for GMDA. In the last year negative earnings were reported.
  • Also next year GMDA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GMDA Price Earnings VS Forward Price EarningsGMDA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GMDA Per share dataGMDA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6

4.3 Compensation for Growth

  • GMDA's earnings are expected to grow with 51.21% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y50.84%
EPS Next 3Y51.21%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • GMDA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

GAMIDA CELL LTD

NASDAQ:GMDA (4/5/2024, 8:00:00 PM)

After market: 0.032 0 (-2.14%)

0.0327

-0.01 (-18.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-27
Earnings (Next)05-07
Inst Owners0.24%
Inst Owner Change0%
Ins Owners3.15%
Ins Owner Change0%
Market Cap4.34M
Revenue(TTM)1.78M
Net Income(TTM)-63.00M
Analysts80
Price Target4.42 (13416.82%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)84.15%
Min EPS beat(2)74.12%
Max EPS beat(2)94.18%
EPS beat(4)3
Avg EPS beat(4)28.83%
Min EPS beat(4)-56.46%
Max EPS beat(4)94.18%
EPS beat(8)5
Avg EPS beat(8)12.83%
EPS beat(12)8
Avg EPS beat(12)12.1%
EPS beat(16)10
Avg EPS beat(16)4.74%
Revenue beat(2)1
Avg Revenue beat(2)-34.95%
Min Revenue beat(2)-72.29%
Max Revenue beat(2)2.4%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)8.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.3%
Revenue NY rev (1m)18.03%
Revenue NY rev (3m)17.94%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.44
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.63
EYN/A
EPS(NY)-0.57
Fwd EYN/A
FCF(TTM)-0.6
FCFYN/A
OCF(TTM)-0.6
OCFYN/A
SpS0.01
BVpS-0.02
TBVpS-0.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -61.65%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 18.53%
FCFM N/A
ROA(3y)-61.87%
ROA(5y)-54.88%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 53.41%
Cap/Sales 60.7%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.16
Quick Ratio 2.09
Altman-Z -8.53
F-Score4
WACC5.78%
ROIC/WACCN/A
Cap/Depr(3y)1665.53%
Cap/Depr(5y)1683.47%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)49.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.67%
EPS Next Y9.37%
EPS Next 2Y50.84%
EPS Next 3Y51.21%
EPS Next 5Y50.79%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year808.75%
Revenue Next 2Y935.67%
Revenue Next 3Y499.3%
Revenue Next 5Y182.44%
EBIT growth 1Y3.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-4.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-12.35%
OCF growth 3YN/A
OCF growth 5YN/A

GAMIDA CELL LTD / GMDA FAQ

Can you provide the ChartMill fundamental rating for GAMIDA CELL LTD?

ChartMill assigns a fundamental rating of 2 / 10 to GMDA.


Can you provide the valuation status for GAMIDA CELL LTD?

ChartMill assigns a valuation rating of 1 / 10 to GAMIDA CELL LTD (GMDA). This can be considered as Overvalued.


Can you provide the profitability details for GAMIDA CELL LTD?

GAMIDA CELL LTD (GMDA) has a profitability rating of 1 / 10.


Can you provide the financial health for GMDA stock?

The financial health rating of GAMIDA CELL LTD (GMDA) is 2 / 10.